Drazin Michael B 4

What Happened

• Michael B. Drazin, Chief Financial Officer of Medline (MDLN), was granted a series of equity awards reported on Form 4 covering transactions dated December 16, 2025 (and a small grant on March 5, 2026). The filing shows aggregate grants totaling about 3,689,540 units (a mix of Class B common shares, restricted stock units (RSUs) and various incentive/derivative units). Most grants are recorded with no purchase price (N/A); one small grant of 25,788 shares on March 5, 2026 is shown at $0.00.
• These were awards/grants (code A) — not open-market purchases or sales — so they represent compensation or reclassification events rather than insider buying or selling for cash.

Key Details

• Transaction dates and prices:
  • Dec 16, 2025: multiple awards totaling roughly 3,663,752 units recorded at N/A (various classes/derivative interests).
  • Mar 5, 2026: 25,788 shares reported at $0.00.
• Shares/units shown in the filing total ~3,689,540 across several line items (see full Form 4 for exact breakdown).
• Shares owned after transaction: not disclosed in the provided summary of the filing.
• Notable footnotes:
  • F1/F4: Some securities reflect a reclassification of Medline Holdings, LP interests prior to the company’s IPO; Common Units can be exchanged one-for-one for Class A shares under an Exchange Agreement.
  • F2: Class B common stock reported has no economic value and carries one vote per share; those Class B shares cancel if their corresponding Common Units are exchanged for Class A stock.
  • F3: Some RSUs vest 25% on June 15, 2026, then the remaining 75% in three equal annual installments starting March 1, 2027.
  • F5–F9/F10: Several grants are “Incentive Units” (profit‑interest style awards) with varying vesting schedules (some partially vested, others vesting in equal annual installments beginning in 2026); vested incentive units can be converted to Common Units per the stated formula and then exchanged for Class A shares.
• Filing timeliness: The Form 4 was filed March 6, 2026 reporting December 16, 2025 transactions — this is a delayed filing and reduces near-term transparency for investors.

Context

• These are awards/derivative-type grants (not market purchases or sales). Incentive Units function like profit‑interests/stock-appreciation vehicles and may convert into Common Units and then into Class A stock under the Exchange Agreement; RSUs convert to stock on vesting. Class B shares reported can carry voting rights but, per footnote, have no economic value until/if converted.
• For retail investors: awards are compensation-related and do not, by themselves, indicate buying/selling sentiment. The late filing is a disclosure point to watch; consult the full Form 4 and the company’s S‑1/Proxy for complete conversion/vesting mechanics and any post-vesting sales or holdings updates.